BioMedNewsBreaks

WednesdayNov 22, 2023 3:22 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Featured Guest in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk about the company and its achievements and potential. Specifically, the two talked about the company’s recent signing of a definitive agreement to merge with GEDiCube, a United-Kingdom-based medical artificial intelligence (“AI”) company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. During the interview, Dybul discussed the plan to rebrand GEDiCube…

Continue Reading

WednesdayNov 22, 2023 2:56 pm

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Issues Warning to Shareholders

Safety Shot (NASDAQ: SHOT) today announced that it has come to its attention that there are several disclosed short sellers publishing malicious defamatory, inaccurate articles about Safety Shot and its management in a willful attempt to scare SHOT investors out of their positions in hopes of getting them to sell their shares so they can then buy at a lower cost to cover their disclosed short position. According to the announcement, several groups are currently being sued in federal court for publishing these fraudulent articles on other companies, and Safety Shot will be preparing a similar lawsuit against these Cayman…

Continue Reading

WednesdayNov 22, 2023 1:16 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluating Berubicin. According to the announcement, the data showed the comparability of the patient demographics in the two arms of the study, and of the safety data for each therapeutic modality in treating recurrent Glioblastoma Multiforme (“GBM”). The data was presented in a poster presentation at the 28th annual Society of NeuroOncology meeting, which was held Nov. 15–19, 2023, in Vancouver,…

Continue Reading

TuesdayNov 21, 2023 3:15 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Poised to Spearhead Advancements in Battle Against Diseases, Harness Cutting-Edge AI Technology

Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy, recently announced a definitive agreement to combine with the advanced AI company GEDiCube International Ltd, rebranding as Renovaro AI. “The company has also announced the addition of three new members to its board of directors – Avram Miller, Leni Boeren and Ruud Hendriks. Leni Boeren brings a 40-year career in the financial sector, with banking roles at Paribas and Rabobank… Ruud Hendriks brings over 35 years of experience in asset management, having held senior roles at some of the most established financial institutions… Avram Miller is…

Continue Reading

TuesdayNov 21, 2023 2:03 pm

BioMedNewsBreaks – Biofrontera Inc. (NASDAQ: BFRI) Announces $4.5M Registered Direct

Biofrontera (NASDAQ: BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, recently entered into a securities purchase agreement with a certain institutional investor, pursuant to which the company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase an aggregate of up to 1,807,000 shares of common stock, at an exercise price of $3.55 per share of common stock. According to the announcement, the warrants are exercisable immediately upon issuance and will expire five years following the date of issuance.…

Continue Reading

TuesdayNov 21, 2023 1:57 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Launches Carlsbad-Based CDMO GMP Manufacturing Facility

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the opening of its new manufacturing facility in Carlsbad, California, to meet the growing demand for its products. The facility will handle orders that SOHM has received and expects to receive in the near future, while its main facility in downtown San Diego undergoes renovation to become fully operational. “I am very proud to launch this facility with our SOHM team members. This Carlsbad facility is conveniently located right at the mid-way between two importing commercial hubs: Los Angeles…

Continue Reading

TuesdayNov 21, 2023 1:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Approval of the Plan of Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that FSD Pharma securityholders (as defined in the announcement) have approved the previously disclosed plan of arrangement under section 182 of the Business Corporations Act (Ontario) pursuant to which common shares in the capital of Celly Nutrition Corp. (“Celly Nu”) will be distributed to the holders of class A multiple voting shares, class B subordinate voting shares, and holders of warrants exercisable for the purchase of class B subordinate voting shares as outlined in the press…

Continue Reading

MondayNov 20, 2023 2:31 pm

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Set for Dec. 7 California Launch

Safety Shot (NASDAQ: SHOT) today announced the west coast launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot is a nutraceutical functional beverage, created by industry experts and validated by research, that accelerates the body’s break-down of alcohol while aiding in recovery and rehydration. “Our west coast launch in the Los Angeles area is aligned with our national online direct-to-consumer sales launch through our own website and through Amazon. We are super excited to have people try Safety Shot. We have given out…

Continue Reading

MondayNov 20, 2023 2:12 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants will be exercisable immediately upon issuance, at an exercise price of $1.30 per share, and will expire five years after the initial exercise date. Subject…

Continue Reading

FridayNov 17, 2023 1:34 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Opportunity in Largely Untapped Precision Medicine Market

Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The move brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights and targeted immunotherapies. “According to CEO Dr. Mark Dybul, MD, the AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the precision medicine market, which Renovaro is positioned to capture a substantial share of the largely untapped market. The immunotherapy division plans to…

Continue Reading